Semax raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-16. Anything still debated is marked as such rather than presented as settled.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It corresponds to the ACTH(4-7) fragment extended at the C-terminus by a Pro-Gly-Pro tripeptide, an addition intended to slow enzymatic breakdown. The molecular formula is C37H51N9O10S and the molecular mass is approximately 814 daltons. In the literature it is often described as an ACTH(4-10) analog, although that label reflects a naming convention as much as a precise structural relationship. The compound was developed in Russia and remains most closely associated with that research tradition.
Laboratory descriptions of the material are consistent across suppliers. It appears as a white to off-white lyophilized powder that dissolves readily in water and in polar organic solvents such as dimethyl sulfoxide. Aqueous solutions are clear and colorless at low concentrations. Because the peptide contains methionine, oxidation at the sulfur atom is a recognized degradation pathway, and handling notes usually call for protected, desiccated storage. Reported purity for research-grade lots is generally above 95 percent as measured by reversed-phase high-performance liquid chromatography.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Analogue of the ACTH(4-10) fragment |
| Amino acid sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Single-letter form MEHFPGP |
| Molecular formula | C37H51N9O10S | Free peptide, nominal mass near 814 Da |
| First registration | 1994, Russia | Nasal formulation for neurological indications |
| Typical purity grade | 95% or higher by HPLC | Research material; higher grades used as reference standards |
Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.
Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.
Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.
== External links == NLM Hazardous Substances Databank – Plutonium, Radioactive Table of nuclides with 239Pu data at Kaye and Laby Online Half-life of Plutonium-239 Archived 2011-08-15 at the Wayback Machine
A 2015 study concluded that minorities have been disproportionately arrested for drug offenses and the difference could not "be explained by differences in drug offending, non-drug offending, or residing in the kinds of neighborhoods likely to have heavy police emphasis on drug offending." The nature of the U.S.-sponsored war on drugs creates two dangerous consequences that often go largely unnoticed: racial profiling and irreversible harm done through legislation, both at the international and domestic spheres. With the introduction of the USA Patriot Act in October 2001 the United States appears to employ a surveillance strategy that ultimately weakens the civil rights of those affected, often through unbalanced criminal proceedings. These policies fail to acknowledge South American women's realities, which are intersectionality observed through socioeconomic positions, cultural and gender expectations, and unfamiliarity with the English language in criminal procedures Studies have shown the increase of racial profiling in Latino women as a method to deter the war on drugs, creating power imbalances as U.S. policies are pushed to national South American governments. The war on drugs has caused irreversible consequences to Latino women that should shape future understanding of the harms of racial profiling and not addressing the deeper issues of individual realities in the conflict.
=== New Granada (Colombia) === Sailing southeast, the sloop entered the Gulf of Batabano, passing Isla de Pinos and navigating the challenging Jardines y Jardinillos archipelago, a region earlier named by Columbus. Humboldt measured latitudes and studied water characteristics, noting the solitude of the area, which was once frequented by fishermen. The journey was slow, with stops for geological and botanical observations. The crew’s cruelty toward wildlife disturbed Humboldt. After several days, the ship entered open water and was driven off course by winds toward the Cayman Islands before resuming its route to the Colombian coast. On March 24, the ship arrived in the Gulf of Santa Marta, enduring rough weather before seeking shelter near the Rio Sint. The travelers landed in a remote area, where locals regarded them with suspicion. Humboldt met a fellow German among palm wine workers, who offered insights about the climate but little else. After collecting botanical specimens, the travelers faced further storms at sea, nearly capsizing before finally finding shelter. Humboldt attempted to make astronomical observations to determine longitude but was prevented by the captain due to difficult terrain. An encounter with escaped enslaved people left Humboldt reflecting on the region’s hardships and the blunted sympathy caused by slavery. Arriving in Cartagena, Humboldt and Bonpland spent six days confirming geographical data and exploring the area. Cartagena, a key Spanish colonial port, faced challenges in defending its harbor.
== History == Macrophages were first discovered late in the 19th century by zoologist Élie Metchnikoff. Metchnikoff revolutionized the branch of macrophages by combining philosophical insights and the evolutionary study of life. Later on, Van Furth during the 1960s proposed the idea that circulating blood monocytes in adults allowed for the origin of all tissue macrophages. In recent years, publishing regarding macrophages has led people to believe that multiple resident tissue macrophages are independent of the blood monocytes as it is formed during the embryonic stage of development. Within the 21st century, all the ideas concerning the origin of macrophages (present in tissues) were compiled together to suggest that physiologically complex organisms, from macrophages independently by mechanisms that don't have to depend on the blood monocytes.
Under mild reduction, the naturally occurred (-)-ptaquilosin 11 was obtained. The Yamada's synthesis proceeded in 20 steps with an overall yield of 2.9%. Similarly, the unnatural (+)-enantiomer of ptaquilosin was synthesized from the diastereomer of 2.
Sources: en.wikipedia.org
Mindlin (1928), engineer, Medal for Merit and ASME Medal recipient Harold Charles Bold (1929), botanist Jule Eisenbud (1929), psychiatrist known for research into parapsychology Theodore Lidz (1930), Sterling Professor of psychiatry at Yale; expert on schizophrenia Judd Marmor (1930), psychoanalyst and psychiatrist on homosexuality Herbert L. Anderson (1931), director of the Enrico Fermi Institute, professor of the University of Chicago Paul E. Queneau (1931), professor of metallurgical engineering at Dartmouth College Bernard Glueck Jr. (1933), psychiatrist, former president of the American Psychopathological Association Irving Kaplan (1933), chemist, professor at Massachusetts Institute of Technology Leo Rangell (1933), psychoanalyst; president of the International Psychoanalytical Association and the American Psychoanalytic Association John K. Lattimer (1935), urologist, ballistics expert, and inveterate collector Emanuel Papper (1935), anesthesiologist, dean of the Miller School of Medicine at the University of Miami 1969–1981 Norman Foster Ramsey Jr. (1935), winner of the Nobel Prize in Physics Robert Marshak (1936), president of the American Physical Society and president of the City College of New York Julian Schwinger (1936), winner of the Nobel Prize in Physics; posited the Schwinger effect Barry Commoner (1937), leading environmentalist, former editor of Science Illustrated magazine Francis J. Ryan (1937), professor of zoology at Columbia University Boris Jacobsohn (1938), professor of Physics at the University of Washington David B.
=== Back to Trials === In February 2019, SHIELD Illinois partnered with the United States District Court for the Northern District of Illinois to provide SARS-CoV-2 screening to jurors, attorneys, employees, and other courthouse visitors. The program required all jurors to test with SHIELD Illinois before reporting for voir dire while employees were tested weekly. This partnership allowed jury trials to resume in the Northern District while maintaining a safe and healthy working environment for everyone involved.
The BNP test is used as an aid in the diagnosis and assessment of severity of heart failure. A recent meta-analysis concerning effects of BNP testing on clinical outcomes of patients presenting to the emergency department with acute dyspnea revealed that BNP testing led to a decrease in admission rates and decrease in mean length of stay, although neither was statistically significant. Effects on all cause hospital mortality was inconclusive. The BNP test is also used for the risk stratification of patients with acute coronary syndromes.
== History == Martin Freund and (Jakob) Edmund Speyer of the University of Frankfurt in Germany published the first synthesis of oxycodone from thebaine in 1916. When Freund died, in 1920, Speyer wrote his obituary for the German Chemical Society. Speyer, born to a Jewish family in Frankfurt am Main in 1878, became a victim of the Holocaust. He died on 5 May 1942, the second day of deportations from the Lodz Ghetto; his death was noted in the ghetto's chronicle. The first clinical use of the drug was documented in 1917, the year after it was first developed. It was first introduced to the U.S. market in May 1939. In early 1928, Merck introduced a combination product containing scopolamine, oxycodone, and ephedrine under the German initials for the ingredients SEE, which was later renamed Scophedal (SCOpolamine, ePHEDrine, and eukodAL) in 1942. It was last manufactured in 1987 but can be compounded. This combination is essentially an oxycodone analogue of the morphine-based "twilight sleep", with ephedrine added to reduce circulatory and respiratory effects. The drug became known as the "Miracle Drug of the 1930s" in Continental Europe and elsewhere and it was the Wehrmacht's choice for a battlefield analgesic for a time. The drug was expressly designed to provide what the patent application and package insert referred to as "very deep analgesia and profound and intense euphoria" as well as tranquillisation and anterograde amnesia useful for surgery and battlefield wounding cases.
Sources: en.wikipedia.org
=== Oxytocics === Certain lysergamides like ergometrine and methylergometrine are used clinically as oxytocic agents. The oxytocic effects of these drugs are thought to most likely be mediated by agonism of serotonin 5-HT2 receptors in uterine smooth muscle tissue.
Biomedical sciences are a set of sciences applying portions of natural science or formal science, or both, to develop knowledge, interventions, or technology that are of use in healthcare or public health. Such disciplines as medical microbiology, clinical virology, clinical epidemiology, genetic epidemiology, and biomedical engineering are medical sciences. In explaining physiological mechanisms operating in pathological processes, however, pathophysiology can be regarded as basic science. Biomedical Sciences, as defined by the UK Quality Assurance Agency for Higher Education Benchmark Statement in 2015, includes those science disciplines whose primary focus is the biology of human health and disease and ranges from the generic study of biomedical sciences and human biology to more specialised subject areas such as pharmacology, human physiology and human nutrition. It is underpinned by relevant basic sciences including anatomy and physiology, cell biology, biochemistry, microbiology, genetics and molecular biology, pharmacology, immunology, mathematics and statistics, and bioinformatics. As such the biomedical sciences have a much wider range of academic and research activities and economic significance than that defined by hospital laboratory sciences. Biomedical Sciences are the major focus of bioscience research and funding in the 21st century.
==== Mass-sensitive peptide biosensors ==== Mass-sensitive Peptide Biosensors make use of platforms like quartz crystal microbalance (QCM) or piezoelectric sensors. These biosensors detect changes in mass or resonance frequency upon target binding, providing a label-free detection in real time. Because they function label-free and are efficient in identifying cells, virion, poisons, and large biomacromolecules since the signal is directly dependent on mass accumulation.
Sources: en.wikipedia.org
Registered medical products are most often 0.1% nasal drops. Research suppliers ship lyophilized powder, usually in milligram quantities, which is dissolved before use. The active peptide is the same in both cases; presentation and excipients differ.
No. The peptide is synthetic, although it is modelled on a fragment of a naturally occurring hormone. ACTH(4-10) is generated when ACTH is cleaved, but the Pro-Gly-Pro extension is not a known endogenous sequence. It is therefore a designed analogue rather than a natural metabolite.
The label reflects reported effects on attention, memory and recovery after neurological injury in regional clinical reports. Those reports are mostly small and have not been widely replicated outside the region. The classification is descriptive and does not imply a single defined mechanism.
It is registered as a pharmaceutical product in Russia, where it is typically supplied as a nasal solution. In most other countries it is not an approved drug and is traded as a research chemical instead. Approval status depends entirely on the jurisdiction involved.